SK Life Science, Inc.
Clinical trials sponsored by SK Life Science, Inc., explained in plain language.
US subsidiary of SK Biopharmaceuticals, developing CNS drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with focal seizures: cenobamate trial underway Results expected Nov 2026 (estimated)
- New epilepsy drug tested as standalone treatment Results expected May 2027 (estimated)
-
New hope for kids with focal seizures: cenobamate trial underway
Disease control OngoingThis phase 3 trial is testing the safety and tolerability of the drug cenobamate (Xcopri) in 140 children aged 2 to 17 with partial-onset (focal) seizures. Researchers will monitor side effects, lab results, and drug levels in the blood. The study is open-label, meaning everyone …
Phase 3 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Sep 10, 2026 04:00 UTC
-
New epilepsy drug tested as standalone treatment
Disease control OngoingThis study tests whether cenobamate, already approved for epilepsy, works well when used alone in adults with partial-onset seizures. About 49 participants will take either 100 mg or 200 mg daily, and researchers will track how many become seizure-free for 26 weeks. The goal is t…
Phase 4 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC